Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Developing a way to track patients enrolled in Children's Oncology Group studies will help doctors gather long-term follow-up information and may help the study of cancer in the future.
PURPOSE: This clinical trial is studying long-term follow-up in patients who are or have participated in Children's Oncology Group studies.
| Condition | Intervention |
|---|---|
|
Brain and Central Nervous System Tumors Chronic Myeloproliferative Disorders Leukemia Long-term Effects Secondary to Cancer Therapy in Children Lymphoma Lymphoproliferative Disorder Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Precancerous Condition Unspecified Childhood Solid Tumor, Protocol Specific |
Other: survey administration Procedure: assessment of therapy complications Procedure: long-term screening Procedure: study of high risk factors |
| Study Type: | Observational |
| Official Title: | Umbrella Long-Term Follow-Up Protocol |
- Development of mechanism for tracking and retaining patients enrolled on COG protocols [ Designated as safety issue: No ]
- Maintenance of regular, lifetime contact with patients [ Designated as safety issue: No ]
- Location of targeted patients lost to follow up [ Designated as safety issue: No ]
- Current patient contact information and reported health status updates [ Designated as safety issue: No ]
- Collection of protocol-specific outcome data [ Designated as safety issue: No ]
- Collection of cumulative therapeutic exposure data [ Designated as safety issue: No ]
| Estimated Enrollment: | 906 |
| Study Start Date: | May 2007 |
| Estimated Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To develop a mechanism for tracking and retaining patients enrolled on COG protocols.
- To maintain regular, lifetime contact with patients in order to obtain current identification and contact information, and self/parent-reported health status.
- To locate patients who are lost-to-follow-up for COG (or Legacy Group) protocols targeted for follow-up by the Long-Term Follow-Up Center (LTFC).
- To provide current patient contact information and self/parent-reported health status updates to the COG Statistics and Data Center (SDC) and to each patient's COG institution.
- To facilitate collection of protocol-specific outcome data through collaboration with the COG Late Effects Committee, the SDC, and the member institutions.
- To collect cumulative therapeutic exposure data (via therapeutic summaries completed online by treating institutions) on patients completing active therapy.
OUTLINE: This is an umbrella protocol for all long-term follow-up at COG institutions. Approximately 6 months after completion of therapy patients receive a mailed packet introducing the Long-Term Follow-Up Center (LTFC) and containing information related to their individualized, protocol-specific follow-up guidelines. Patients are asked to complete a patient response form, verify information provided in packet, update contact information, and complete a Health Status Update Form. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients receive protocol-specific automatic reminders, and may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Must be newly diagnosed with a primary malignancy and enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy OR must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial calling for long-term follow-up, including any of the following:
Hodgkin lymphoma
- CCG-5942
- POG-9425
- POG-9426
- COG-AHOD0031
Brain tumor
- CCG-A9961
Acute lymphoblastic leukemia
- COG-ALTE02C2
Neuroblastoma
- COG-A3973
Rhabdomyosarcoma
- IRS-III
- IRS-IV-Stage 1
- IRS-IV-Stage 2/3
- IRS-IV-Stage/Group 4
- Must reside in the U.S. during trial enrollment
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations
Show 113 Study Locations| Study Chair: | Smita Bhatia, MD, MPH | Beckman Research Institute |
| Investigator: | Dennis Deapen, DrPH | USC/Norris Comprehensive Cancer Center |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00736749 History of Changes |
| Other Study ID Numbers: | CDR0000590123, COG-ALTE05N1 |
| Study First Received: | August 15, 2008 |
| Last Updated: | April 7, 2011 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
acute myeloid leukemia/transient myeloproliferative disorder myelodysplastic/myeloproliferative neoplasm, unclassifiable long-term effects secondary to cancer therapy in children unspecified childhood solid tumor, protocol specific accelerated phase chronic myelogenous leukemia acute undifferentiated leukemia atypical chronic myeloid leukemia, BCR-ABL negative blastic phase chronic myelogenous leukemia childhood acute lymphoblastic leukemia in remission childhood acute myeloid leukemia in remission childhood chronic myelogenous leukemia chronic myelomonocytic leukemia chronic phase chronic myelogenous leukemia juvenile myelomonocytic leukemia mast cell leukemia |
meningeal chronic myelogenous leukemia progressive hairy cell leukemia, initial treatment prolymphocytic leukemia secondary acute myeloid leukemia stage 0 chronic lymphocytic leukemia stage I chronic lymphocytic leukemia stage II chronic lymphocytic leukemia stage III chronic lymphocytic leukemia stage IV chronic lymphocytic leukemia T-cell large granular lymphocyte leukemia untreated childhood acute lymphoblastic leukemia untreated childhood acute myeloid leukemia and other myeloid malignancies untreated hairy cell leukemia stage I childhood Hodgkin lymphoma stage II childhood Hodgkin lymphoma |
Additional relevant MeSH terms:
|
Myeloproliferative Disorders Myelodysplastic-Myeloproliferative Diseases Neoplasms Leukemia Lymphoma Lymphoproliferative Disorders Multiple Myeloma Neoplasms, Plasma Cell Plasmacytoma Myelodysplastic Syndromes Preleukemia Nervous System Neoplasms Precancerous Conditions Lymphoma, Non-Hodgkin Central Nervous System Neoplasms |
Lymphoma, Large-Cell, Anaplastic Neoplasms by Histologic Type Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Bone Marrow Diseases Neoplasms by Site Nervous System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013